New drug GRT6019 takes first step toward duchenne treatment
NCT ID NCT07347548
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests the safety and tolerability of a new drug called GRT6019 in 24 healthy men. Participants receive multiple doses over 4 weeks and are monitored for side effects and how the drug moves through the body. The goal is to see if GRT6019 is safe enough to study further in people with Duchenne muscular dystrophy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GRT6019
What this could lead to
If safe, this could lead to larger trials testing GRT6019 as a potential treatment for Duchenne muscular dystrophy.
What could go wrong
This is a very early, small trial in healthy men, not patients. It only tests safety and drug levels, not whether it works for DMD. Many early-stage drugs fail to show benefit later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Long-Term DMD Study of ENTR-601-44/45 (NCT07682129)
- DMD Heart Function Study Using MRI (NCT07674758)
- Digital Monitoring for Upper Limb Function in DM NCT07664124
- GLP-1 Drug Safety in Duchenne Muscular Dystrophy NCT07642635
- DYNE-251 for Duchenne Muscular Dystrophy (NCT07608432)
- Duchenne EHR Study: Better Data for Better Care NCT07609394
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biotrial Clinical Pharmacology Unit
Rennes, 35042, France